期刊文献+

血浆尾加压素Ⅱ浓度与冠状动脉病变程度的关系 被引量:10

Correlation between serum levels of urotensin Ⅱ and severity of coronary artery disease
在线阅读 下载PDF
导出
摘要 目的:研究血浆尾加压素Ⅱ浓度与冠状动脉病变程度的关系。方法:在100例已知或怀疑冠心病患者中行冠脉造影检查,并用酶联免疫法测量血浆中尾加压素Ⅱ水平。依照冠脉造影结果分为非冠心病组(狭窄<50%)和冠心病组(狭窄≥50%),病变程度定量采用Micheal评分系统。结果:血浆尾加压素Ⅱ浓度在非冠心病组和冠心病组间无统计学差异(P>0.05),冠脉正常或极轻微病变组(评分<3)与冠脉病变严重组(评分≥9)间有统计学差异(P<0.05)。血浆尾加压素Ⅱ浓度与冠状动脉病变评分正相关(r=0.213,P<0.05),与其他危险因素及危险评分不相关。多变量回归分析尾加压素Ⅱ是继年龄、血糖异常、高血压之后的独立危险因素。结论:在严重冠脉病变患者血浆中尾加压素Ⅱ水平显著升高,并且尾加压素Ⅱ水平与冠脉病变程度明显正相关。 Objective:To examine the correlation between urotensin Ⅱ concentration and the severity of coronary artery disease(CAD).Methods:We studied urotensin Ⅱ concentration in 100 patients with known or suspected CAD referred for cardiac catheterization.Based on coronary angiograms, subjects were classified as having mild or without CAD(stenosis〈50%)and marked CAD(stenosis≥50%). Micheal score system was used to estimate the severity of CAD.Results:Urotensin Ⅱ concentration in the marked CAD group had no difference compared with mild or without CAD group (1.95±1.18ng/ml vs 2.04±1.47ng/ml,P〉0.05), but higher in severer group (score≥9) than in normal or nearly normal group (score〈3),(2.50±1.62ng/ml vs 1.61±1.05ng/ml,P〈0.05). Urotensin Ⅱ concentration had no relationship with other known risk factors,but it correlated to CAD severity (r=0.213,P〈0.05).In multiple regression analysis,Urotensin Ⅱ was one determinant of the severity of CAD, other than age, abnornlal glucose,hypertension and gender.Conclusion:Urotensin Ⅱ concentrations are elevated in severe CADs and there is a significant relationship between urotensin Ⅱ concentration and CAD severity.
出处 《中日友好医院学报》 2008年第1期3-6,共4页 Journal of China-Japan Friendship Hospital
关键词 动脉粥样硬化 尾加压素Ⅱ 冠状动脉疾病 atherosclerosis urotensin Ⅱ coronary artery disease
  • 相关文献

参考文献14

  • 1张丽芳,丁文惠,柯元南.尾加压素Ⅱ与动脉粥样硬化[J].中华心血管病杂志,2007,35(5):491-493. 被引量:5
  • 2Micheal FR,Paul JN,Ian HC,et al.Lipoprotein predictors of the severity of coronary artery disease in men and women [J].Circulation, 1985,71(5):881-888.
  • 3Cickroft DW,Gauh MH.Prediction of creatinine clearance from serum creatinine[J]. Nephron, 1976, 16(1):31-41.
  • 4Deckers JW, Goedhart DM, Boersma E,et al.Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk [J]. Eur Heart J,2006,27 (7):796-801.
  • 5Hassan GS,Douglas SA,Ohlstein EH,et al.Expression of urotensin-Ⅱ in human coronary atherosclerosis[J].Peptide, 2005,26(12):2464-2472.
  • 6Heringlake M,Kox T,Uzun O,et al.The relationship between urotensin Ⅱ plasma immunoreactivity and left ventricular filling pressures in coronary artery disease [J].Regul Pept, 2004,121( 1-3):129-136.
  • 7Sohail QK,Sanjay SB,Paulene Q,et al.Urotensin Ⅱ is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans[J]. Int J Cardiol,2007,117(3):323-328.
  • 8方石虎,李志樑,吴宏超,唐朝枢,陆青,刘海潮,严全能.冠心病患者血浆尾加压素Ⅱ的临床研究[J].第一军医大学学报,2004,24(5):563-565. 被引量:21
  • 9Joyal D,Huynh T,Aiyar N,et al.Urotensin-Ⅱ levels in acute coronary syndromes[J].Int J Cardiol,2006,108(1):31-35.
  • 10史力斌,丁文惠,杨俊娟,唐朝枢.缺血性心脏病患者血浆尾加压素Ⅱ水平的变化及意义[J].中华内科杂志,2001,40(9):634-635. 被引量:5

二级参考文献51

  • 1黎娜,朱文玲,陈莲凤,柯元南.缬沙坦和卡托普利对兔血管平滑肌细胞组织因子和组织因子途径抑制物表达及活性的影响[J].中华心血管病杂志,2006,34(10):922-928. 被引量:5
  • 2Bern HA, Pearson D, Larson BA, et al. Neurohormones from fish tails: the caudal neurosecretory system I. "Urophysiology" and the caudal neurosecretory system of fishes [J]. Recent Prog Horm Res,1985, 41(5): 533-52.
  • 3Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord[J]. Proc Natl Acad Sci USA, 1998, 95(26): 15803-8.
  • 4Ames RS, Sarau HM, Chambers JK, et al. Human urotensin- Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J]. Nature, 1999, 401(6750): 282-6.
  • 5Douglas SA, Ohlstein EH. Human urotensin- Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease [J]. Trends Cardiovasc Med, 2000, 10(6): 229-37.
  • 6Katano Y, Ishihata A, Aita T, et al. Vasodilator effect ofurotensin Ⅱ, one of the most potent vasoconstricting factors, on rat coronary arteries[J]. Eur J Pharmacol, 2000, 402(1-2): R5-7.
  • 7Gray GA, Jones MR, Sharif I, et al. Human urotensin Ⅱ increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition [J]. Life Sci,2001, 69(2): 175-80.
  • 8Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect ofurotensin Ⅱ with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells[J]. Circulation, 2001, 104(1): 16-8.
  • 9Meyers D, Galbraith A J, Bett N, et al. Elevated plasma levels of human urotensin- Ⅱ immunoreactivity in congestive heart failure[J].Am J Physiol Heart Circ Physiol, 2003, 285(4): 1576-81.
  • 10Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA, 1998,95 (26) : 15803- 15808.

共引文献28

同被引文献114

引证文献10

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部